# A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

> **NCT02307513** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 207 (actual)

## Conditions studied

- Behçet's Syndrome

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02307513
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-30
- **Primary completion:** 2017-09-25
- **Final completion:** 2020-07-17
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02307513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02307513, "A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02307513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*